<DOC>
	<DOC>NCT00908362</DOC>
	<brief_summary>Airway dendritic cells (DCs) play a key role in smoke-related lung diseases. In this study, the researchers investigate the effects of fluticasone and salmeterol on human airway DCs in smokers. The researchers hypothesize that fluticasone and salmeterol impact on the number and the characteristics of airway DCs in smokers.</brief_summary>
	<brief_title>Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Men aged 30 60 years At least 15 years of smoking Current smoker, at least 10 cigarettes per day Any acute or chronic disease (except COPD oder hypertension) Any regular medication (except drugs against hypertension) FEV1 &lt; 80% predicted Oxygen saturation &lt; 90% Acute infections of the lower respiratory tract in the last 7 days before the first day of the study</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Dendritic cells</keyword>
	<keyword>Airway</keyword>
	<keyword>Smoker</keyword>
	<keyword>COPD</keyword>
</DOC>